EASD panels recommend insulin acceptance, and highlight shortfalls in DPNP therapy

24 September 2006

A Consensus Report launched at the annual meeting of the European Association for the Study of Diabetes, in Copenhagen, Denmark, is calling for urgent action to drastically improve the management of diabetes, particularly urging the increased acceptance of insulin.

The Report, a rallying cry to the global medical community, was produced by a panel of 25 diabetes experts from 16 different countries, who convened to tackle the growing diabetes epidemic, which is estimated to consume $286.0 billion from worldwide health care budgets each year.

The coalition was formed to look at ways to address this worrying burden using the results of the Pfizer-sponsored OPTIMIZE survey, in which almost 1,500 people with type 2 diabetes from seven countries were questioned about their attitudes to diabetes management, and found significant patient barriers to achieving optimal blood sugar control, with patient resistance to injections being the most significant amongst them.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight